Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Clinical trial NCT01925612 · TERMINATED
Trial details
- NCT number
- NCT01925612
- Sponsor
- Seagen Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-01
- Primary completion
- 2017-05-01
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.